Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 5 months later Jan 1, 2027 → Jun 1, 2028
See other at-risk trials from Alliance for Clinical Trials in Oncology

Record History

The 50 most recent of 86 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jan 1, 2027 to Jun 1, 2028
    • Study completion pushed from Jan 2028 to Jun 1, 2029
  2. Study sites: 783 to 784
    • Eligibility criteria expanded, about 29 words
  3. Site details revised at 3 of 783 sitesv84
  4. Trial sites expanded: 780 → 783 locationsv83
  5. Study sites revised (780)v82
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites revised (780)v81
  2. Study sites: 781 to 780v80
  1. Trial sites expanded: 777 → 781 locationsv79
  2. Study sites: 775 to 777v78
  3. Primary completion date: Jan 2026 to Jan 1, 2027v77
  4. Study sites: 773 to 775v76
  5. Study sites: 771 to 773v75
  6. Study sites revised (771)v74
  7. Study sites: 770 to 771v73
  8. Study sites: 769 to 770v72
  9. Study sites: 757 to 769v71
  10. Study sites: 752 to 757v70
  11. Start date: Aug 2015 to Sep 28, 2015
    • Site details revised at 453 of 752 sites
    v69
  12. Study sites revised (752)v68
  13. Study sites revised (752)v67
  14. Primary completion date: Oct 2024 to Jan 2026
    • Study completion date: Oct 2024 to Jan 2028
    • Site details revised at 447 of 752 sites
    v66
  15. Study sites: 739 to 752v65
  16. Study sites: 736 to 739v64
  17. Study sites: 734 to 736v63
  18. Study sites: 730 to 734v62
  19. Study sites: 727 to 730v61
  20. Study sites: 721 to 727v60
  21. Study sites: 708 to 721v59
  22. Study sites: 705 to 708v58
  23. Site details revised at 8 of 705 sitesv57
  24. Study sites: 700 to 705v56
  25. Study sites: 697 to 700v55
  26. Study sites: 696 to 697v54
  27. Study sites: 694 to 696v53
  28. Study sites: 683 to 694v52
  29. Study sites: 618 to 683v51
  30. Trial status: Suspended to Recruitingv50 Show 5 more changesShow less
    • Enrollment target: 69 to 124
    • Study completion date: Oct 2024
    • Interventions: GSK2256098 (Drug), vismodegib (Drug) to Abemaciclib (Drug), Capivasertib (Drug), FAK Inhibitor GSK2256098 (Drug), Vismodegib (Drug)
    • Site details revised at 618 of 618 sites
    • Study arms: 2 to 4
  31. Study sites revised (618)v49
  32. Re-verified, no change to tracked fieldsv48
  33. Study sites revised (618)v47
  34. Primary completion date: Aug 2021 to Oct 2024v46
  35. Study sites revised (618)v45
  36. 2 versions Re-verified since Feb 5, 2021, no change to tracked fieldsv43-v44
  37. Study sites revised (618)v42
  38. 2 versions Re-verified since Oct 8, 2020, no change to tracked fieldsv40-v41
  39. Study sites revised (618)v39
  40. Study sites revised (618)v38
  41. Study sites revised (618)v37
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Trial Details
NCT Number NCT02523014
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Conditions
(from sponsor)		 Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Related terms Meningioma
Enrollment 124 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov